No registrations found.
ID
Source
Brief title
Health condition
Lower respiratory tract infections
Sponsors and support
Intervention
Outcome measures
Primary outcome
28-day mortality
Secondary outcome
90-day mortality, ICU and hospital LOS, time on the ventilator
Background summary
Background:
At this moment new Corona Virus Disease 2019 (COVID-19) patients will be hospitalised and admitted to the ICU. Little is known of prognostic factors predicting outcome. Which patients will survive and which patients have to stay longer at the ICU and on a ventilator? Can biomarkers like mid-regional proadrenomedullin (MR-proADM) and proarginin-vasopressin (CT-proAVP) at admittance or in serial measurements predict severity and outcome in critically ill COVID-19 patients?
Objective:
The aim of this prospective study is to elucidate whether biomarkers like MR-proADM and CT-proAVP could be used as a marker for severity and prognosis.
Study design:
A single center prospective observational study.
Study population:
SARS-CoV 2 PCR positive patients admitted to the ICU.
Intervention
Blood will drawn during routine daily laboratory rounds and stored at -80 degrees celcius until biomarkers will be assayed later.
The electronic patient database will be searched for survival after 28 and 90 days, LOS ICU and hospital and time on the ventilator.
Main outcome measurement
28-day mortality
Secondary outcome measurement
90-day mortality, length of stay (LOS) ICU and hospital, time on the ventilator.
Study objective
Biomarkers like MR-proADM and CT-proAVP predict severity and outcome in critically ill COVID-19 patients. MR-proADM and CT-proAVP at admittance can be higher in non-survivors and biomarker clearance over the days will be higher in survivors.
Study design
28 days and 90 days after inclusion the electronic patient database will be searched for survival.
Intervention
During routine daily laboratory rounds blood will be stored at -80 C until biomarkers will be assayed later.
Inclusion criteria
SARS-CoV 2 PCR positive patients at the intensive care
Exclusion criteria
SARS-CoV 2 PCR negative OR no SARS-CoV 2 PCR
Design
Recruitment
IPD sharing statement
Plan description
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL8460 |
| Other | Wetenschapsbureau Elisabeth Tweesteden Ziekenhuis : L0977.2020 |